3, 5‐Diiodothyronine protects against cardiac ischaemia–reperfusion injury in male rats. Issue 11 (21st October 2021)
- Record Type:
- Journal Article
- Title:
- 3, 5‐Diiodothyronine protects against cardiac ischaemia–reperfusion injury in male rats. Issue 11 (21st October 2021)
- Main Title:
- 3, 5‐Diiodothyronine protects against cardiac ischaemia–reperfusion injury in male rats
- Authors:
- Louzada, Ruy Andrade
Padron, Alvaro Souto
Marques‐Neto, Silvio Rodrigues
Maciel, Leonardo
Werneck‐de‐Castro, João Pedro
Ferreira, Andrea Claudia Freitas
Nascimento, Jose Hamilton Matheus
Carvalho, Denise Pires - Abstract:
- Abstract : New Findings: What is the central question of this study? 3, 5‐Diiodothyronine (3, 5‐T2) administration increases resting metabolic rate, prevents or treats liver steatosis in rodent models, and ameliorates insulin resistance: what are its effects on cardiac electrical and contractile properties and autonomic regulation? What is the main finding and its importance? Chronic 3, 5‐T2 administration has no adverse effects on cardiac function. Remarkably, 3, 5‐T2 improves the autonomous control of the rat heart and protects against ischaemia–reperfusion injury. Abstract: The use of 3, 5, 3′‐triiodothyronine (T3) and thyroxine (T4) to treat metabolic diseases has been hindered by potential adverse effects on liver, lipid metabolism and cardiac electrical properties. It is recognized that 3, 5‐diiodothyronine (3, 5‐T2) administration increases resting metabolic rate, prevents or treats liver steatosis in rodent models and ameliorates insulin resistance, suggesting 3, 5‐T2 as a potential therapeutic tool. However, a comprehensive assessment of cardiac electrical and contractile properties has not been made so far. Three‐month‐old Wistar rats were daily administered vehicle, 3, 5‐T2 or 3, 5‐T2+T4 and no signs of atrial or ventricular arrhythmia were detected in non‐anaesthetized rats during 90 days. Cardiac function was preserved as heart rate, left ventricle diameter and shortening fraction in 3, 5‐T2‐treated rats compared to vehicle and 3, 5‐T2+T4 groups. Power spectralAbstract : New Findings: What is the central question of this study? 3, 5‐Diiodothyronine (3, 5‐T2) administration increases resting metabolic rate, prevents or treats liver steatosis in rodent models, and ameliorates insulin resistance: what are its effects on cardiac electrical and contractile properties and autonomic regulation? What is the main finding and its importance? Chronic 3, 5‐T2 administration has no adverse effects on cardiac function. Remarkably, 3, 5‐T2 improves the autonomous control of the rat heart and protects against ischaemia–reperfusion injury. Abstract: The use of 3, 5, 3′‐triiodothyronine (T3) and thyroxine (T4) to treat metabolic diseases has been hindered by potential adverse effects on liver, lipid metabolism and cardiac electrical properties. It is recognized that 3, 5‐diiodothyronine (3, 5‐T2) administration increases resting metabolic rate, prevents or treats liver steatosis in rodent models and ameliorates insulin resistance, suggesting 3, 5‐T2 as a potential therapeutic tool. However, a comprehensive assessment of cardiac electrical and contractile properties has not been made so far. Three‐month‐old Wistar rats were daily administered vehicle, 3, 5‐T2 or 3, 5‐T2+T4 and no signs of atrial or ventricular arrhythmia were detected in non‐anaesthetized rats during 90 days. Cardiac function was preserved as heart rate, left ventricle diameter and shortening fraction in 3, 5‐T2‐treated rats compared to vehicle and 3, 5‐T2+T4 groups. Power spectral analysis indicated an amelioration of the heart rate variability only in 3, 5‐T2‐treated rats. An increased baroreflex sensitivity at rest was observed in both 3, 5‐T2‐treated groups. Finally, 3, 5‐T2 Langendorff‐perfused hearts presented a significant recovery of left ventricular function and remarkably smaller infarction area after ischaemia–reperfusion injury. In conclusion, chronic 3, 5‐T2 administration ameliorates tonic cardiac autonomic control and confers cardioprotection against ischaemia–reperfusion injury in healthy male rats. … (more)
- Is Part Of:
- Experimental physiology. Volume 106:Issue 11(2021)
- Journal:
- Experimental physiology
- Issue:
- Volume 106:Issue 11(2021)
- Issue Display:
- Volume 106, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 106
- Issue:
- 11
- Issue Sort Value:
- 2021-0106-0011-0000
- Page Start:
- 2185
- Page End:
- 2197
- Publication Date:
- 2021-10-21
- Subjects:
- 3, 5‐T2 -- autonomous control -- echocardiography -- electrocardiography -- infarct size -- ischaemia–reperfusion injury
Physiology, Experimental -- Periodicals
571.0724 - Journal URLs:
- http://physoc.onlinelibrary.wiley.com/hub/journal/10.1111/(ISSN)1469-445X/issues/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1113/EP089589 ↗
- Languages:
- English
- ISSNs:
- 0958-0670
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3840.040000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24520.xml